FDA announces end to Wegovy and Ozempic drug shortages
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
A recent clinical study of 48 people with signs of moderate alcohol use disorder showed significantly greater reductions in ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results